Esperion Therapeutics Statistics
Total Valuation
ESPR has a market cap or net worth of $202.16 million. The enterprise value is $681.53 million.
Important Dates
The next estimated earnings date is Monday, August 11, 2025, before market open.
| Earnings Date | Aug 11, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ESPR has 198.20 million shares outstanding. The number of shares has increased by 54.12% in one year.
| Current Share Class | 198.20M |
| Shares Outstanding | 198.20M |
| Shares Change (YoY) | +54.12% |
| Shares Change (QoQ) | +0.29% |
| Owned by Insiders (%) | 1.09% |
| Owned by Institutions (%) | 60.08% |
| Float | 196.04M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.76 |
| Forward PS | 0.56 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.63 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.18
| Current Ratio | 1.18 |
| Quick Ratio | 0.72 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -0.62 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -7.17% |
| Return on Invested Capital (ROIC) | -11.83% |
| Return on Capital Employed (ROCE) | -75.31% |
| Revenue Per Employee | $853,862 |
| Profits Per Employee | -$504,020 |
| Employee Count | 304 |
| Asset Turnover | 0.74 |
| Inventory Turnover | 1.57 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -51.20% in the last 52 weeks. The beta is 0.65, so ESPR's price volatility has been lower than the market average.
| Beta (5Y) | 0.65 |
| 52-Week Price Change | -51.20% |
| 50-Day Moving Average | 0.97 |
| 200-Day Moving Average | 1.74 |
| Relative Strength Index (RSI) | 46.77 |
| Average Volume (20 Days) | 3,641,716 |
Short Selling Information
The latest short interest is 24.11 million, so 12.17% of the outstanding shares have been sold short.
| Short Interest | 24.11M |
| Short Previous Month | 26.34M |
| Short % of Shares Out | 12.17% |
| Short % of Float | 12.30% |
| Short Ratio (days to cover) | 4.35 |
Income Statement
In the last 12 months, ESPR had revenue of $259.57 million and -$153.22 million in losses. Loss per share was -$0.81.
| Revenue | 259.57M |
| Gross Profit | 124.12M |
| Operating Income | -39.96M |
| Pretax Income | n/a |
| Net Income | -153.22M |
| EBITDA | -39.92M |
| EBIT | -39.96M |
| Loss Per Share | -$0.81 |
Full Income StatementBalance Sheet
The company has $114.63 million in cash and $594.00 million in debt, giving a net cash position of -$479.37 million or -$2.42 per share.
| Cash & Cash Equivalents | 114.63M |
| Total Debt | 594.00M |
| Net Cash | -479.37M |
| Net Cash Per Share | -$2.42 |
| Equity (Book Value) | -426.21M |
| Book Value Per Share | -2.17 |
| Working Capital | 47.81M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$100.11 million and capital expenditures -$244,000, giving a free cash flow of -$100.35 million.
| Operating Cash Flow | -100.11M |
| Capital Expenditures | -244,000 |
| Free Cash Flow | -100.35M |
| FCF Per Share | -$0.51 |
Full Cash Flow StatementMargins
Gross margin is 47.82%, with operating and profit margins of -15.40% and -59.03%.
| Gross Margin | 47.82% |
| Operating Margin | -15.40% |
| Pretax Margin | -59.03% |
| Profit Margin | -59.03% |
| EBITDA Margin | -15.38% |
| EBIT Margin | -15.40% |
| FCF Margin | n/a |
Dividends & Yields
ESPR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -54.12% |
| Shareholder Yield | -54.12% |
| Earnings Yield | -75.79% |
| FCF Yield | -49.64% |
Analyst Forecast
The average price target for ESPR is $5.93, which is 481.37% higher than the current price. The consensus rating is "Buy".
| Price Target | $5.93 |
| Price Target Difference | 481.37% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 26.39% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ESPR has an Altman Z-Score of -6.19 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.19 |
| Piotroski F-Score | 3 |
